



*Robert M. Hamer, Ph.D.
Professor of Psychiatry and Biostatistics*

Financial Disclosure Statement (October 16, 2009)

In the past 3 years I have served on a DSMB, an advisory board, consulted or advised, or am involved in a contract between UNC and one of the following

Company	Relationship
Acadia	Advised on the design of a clinical trial
Allergan	Served on a DSMB
Alpharma	Served on a Mock Advisory Panel (3 meetings)
AstraZeneca	Statistician on a UNC contract for a clinical trial
Cenerx	Advised on the design and statistical analysis plan of a clinical trial
Corcept	Consultant in the design and analysis of multiple clinical trials
Eli Lilly	Serve on a DSMB
EnabledMD	Served on an Advisory Board
Epix	Advised on the design and analysis of multiple clinical trials
J & J	Consulting statistician on an epidemiological analysis of data from a VA database
NeuroPharmaBoost	Consult on the Design of a Clinical Trial for an antidepressant
Novartis	Served on Advisory Board
Pepper-Hamilton	Advised lawyers regarding a lawsuit (1 teleconference)
Pfizer	Served on multiple DSMBs
PureTechVentures	Consult on the design of a Clinical Trial for an antidepressant
SAS Institute	Taught several seminars for SAS Institute
Schwartz	Served on multiple DSMBs
Solvey	Served on a DSMB
Sanofi-Aventis	Consulted on the design of a clinical trial
Takeda	Consulted on the design of a clinical trial
Winston-Strawn	Expert witness in lawsuit involving Forest, Lundbeck, Sun, and Caraco
Wyeth	Served on an Advisory Board

Additionally, I or my wife own stock in Bristol-Myers Squibb, Amgen, Lilly, Genentech, Proctor and Gamble, Sepracor. Additionally, my wife is retired from Bristol-Myers Squibb has stock options which currently have negative value.

I make no judgment about whether any of these represent a conflict of interest. I leave that to the reader.